中晚期非小细胞肺癌血瘀证回顾性研究
|
摘要
目的通过回顾性临床研究,探索血瘀证在中晚期非小细胞肺癌中的分布规律及其特点,并进一步分析血瘀证与病理类型、肿瘤分期、血凝指标、相兼证候等之间的相关性,从而为临床治疗提供参考。
方法我们以五年内在东直门医院和北京中医医院住院的中晚期非小细胞肺癌病人为研究对象,制定调查表,收集病例。采用描述性分析,了解患者一般资料、病情信息及各凝血指标分布情况,并根据血瘀证诊断标准分为血瘀证组和非血瘀证组,①分析血瘀证患者在非小细胞肺癌患者中的构成比及证候分布特点。②分析血瘀证与一般资料、病理类型、ECOG(Ea stern CooperativeOncology group,ECOG)评分、肿瘤分期、各证型及血凝指标APTT(activatedpartial thrombopla stin time,APTT)、PT(prothrombin time,PT)、TT(thrombin time,TT)、Fbg(fibrinogen,Fbg)、D-二聚体(D-dimer,DD)之间的相关性。
结果①在我们所收集的257例中晚期非小细胞肺癌患者中,气虚、阴虚、痰湿及血瘀均是其临床常见证候,其中血瘀的构成比为72.37%;②在中晚期非小细胞肺癌各证候中,阴虚与血瘀的关系更为密切,在血瘀证患者中阴虚的构成比较非血瘀证患者明显增加;③在中晚期非小细胞肺癌中,血瘀证与年龄、性别、家族史、治疗经过等一般情况以及病理类型无明显相关性,而与肿瘤患者ECOG评分、肿瘤的分期具有一定联系,随着ECOG评分及分期的增加,血瘀证有增多的趋势;④与中晚期非小细胞肺癌非血瘀证相比较,血瘀证患者D-dimer明显升高,差异显著,在多因素逻辑回归分析中也显示出与血瘀证存在明显的正相关。
结论①血瘀证在中晚期非小细胞肺癌中普遍存在,相对于其他证候更为常见;②气虚、阴虚及痰湿作为肺癌的临床常见证候,被认为是影响中晚期非小细胞肺癌血瘀证的主要因素,但相对于非血瘀证,中晚期非小细胞肺癌血瘀证患者存在明显的阴虚致瘀的病理特点;③ECOG评分、肿瘤分期与中晚期非小细胞肺癌血瘀证具有一定的关联性,不仅反映了血瘀证与肿瘤的增殖与转移存在一定的联系,可作为判定中晚期非小细胞肺癌预后的重要因素,而且ECOG评分、肿瘤分期也可以在血瘀证的诊疗中为中医辨病提供参考;④D-dimer与血瘀证的强相关性,不仅反映了中晚期非小细胞肺癌血瘀证患者存在血液的高凝状态,而且还在一定程度上反映了中晚期非小细胞肺癌血瘀证在血凝功能异常方面的实质,并可成为非常实用的临床诊断血瘀证的微观指标;⑤根据中晚期非小细胞肺癌的证候特点及其与血瘀证之间的相关性,我们认为临床应以益气养阴、活血化痰作为中晚期非小细胞肺癌血瘀证的基本治疗策略,不仅体现了中医辨证论治的优势,也充分体现了与肿瘤治疗的统一性。
objective Through the retrospective clinical study,to investigate distribution regularity and characteristics of blood stasis syndrome in advanced non-small cell lung cancer and further to analyze the correlation between blood stasis syndrome and pathological types,tumor stage,haemostasis markers,combination syndromes etc,and then to provide reference for clinical treatment of blood stasis syndrome. Method We took the patients of advanced non-small cell lung cancer from Dong Zhi Mei hospital and Bei Jing hospital of traditional Chinese medicine(TCM) during the recent five years as study cases,and made investigation table,collected cases.Using descriptive analysis to recognize the distribution status of general materials,information of disease and every haemostasis markers,and according to the diagnostic criteria of blood stasis syndrome,these cases were divided into blood stasis syndrome group and non-blood stasis syndrome group.①to analyze the composition ratio and combination syndromes distribution characteristics of patients with blood stasis syndrome;②to analyze the correlation between blood stasis syndrome and general materials, pathological types,tumor stages,every combination syndromes, haemostasis marker APTT(activated partial thromboplastin time),PT (prothrombin time),TT(thrombin time),Fbg(fibrinogen),D-dimer.
Results①Among the collected 257 cases of advanced non-small cell lung cancer,Qi deficiency,yindeficiency,phlegm dampness and blood stasis were all common clinical syndromes,and composition ratio of blood stasis among these syndromes was 72.37%;②Among these syndromes of advanced non-small cell lung cancer,Yin deficiency had a tighter correlation with blood stasis than other syndromes,comparing with non-blood stasis syndrome composition ratio of Yin deficiency was significantly increased in blood stasis syndrome;③In advanced non-small cell lung cancer,blood stasis syndrome had no correlation with general materials of age,sex,family disease history,treatment experience etc and pathological types,but had some correlation with ECOG performance score and the staging of the tumor,with the increase of staging and ECOG score,blood stasis syndrome were with increasing trend;④Comparing with non-blood stasis syndrome of advanced non-small cell lung cancer,D-dimer level of patients with blood stasis syndrome was obviously increased with a significant difference,and also had a significant positive correlation with blood stasis syndrome in multifactor Logistic regression analysis.
Conclusion①In advanced non-small cell lung cancer,blood stasis syndrome was prevalent and more common than other syndromes;②Qi deficiency,yin deficiency and phlegm dampness,which were common syndromes of lung cancer in clinic,all were recognized as primary influencing factors of blood stasis syndrome,but comparing with non-blood stasis syndrome,there was an obvious pathological characteristic of yin deficiency causing blood stasis in blood stasis syndrome of advanced non-small cell lung cancer;③The correlation between ECOG score,tumor staging and blood stasis syndrome,not only reflected some links between blood stasis syndrome and tumor proliferation,matastasis,and thereby ECOG score and tumor staging may were taken to be as important factors for prognosis,but also ECOG score and tumor stage may also provide the basic foundation for disease differentiation of TCM in blood stasis syndrome diagnosis and treatment;④The significant correlation between D-dimer and blood stasis syndrome not only reflected tumor hypercoagulative status in the patients of blood stasis syndrome,but also,to some extent,reflected the blood stasis syndrome essentials of advanced non-small cell lung cancer in terms of blood coagulation disfunction,and then it may was very useful to be taken as a micro-index for clinical diagnosis of blood stasis syndrome;⑤According to the characteristics of blood stasis syndrome combination syndromes and its correlation with blood stasis syndrome, we consider that strengthening qi and nurishing yin,activating blood and removing phlegm should be the basic strategy for the treatment of blood stasis syndrome of advanced non-small cell lung cancer,it not only embodieded the advantage of treatment based on syndrome differentiation of TCM,but also embodied the unity with tumor therapy.
方法我们以五年内在东直门医院和北京中医医院住院的中晚期非小细胞肺癌病人为研究对象,制定调查表,收集病例。采用描述性分析,了解患者一般资料、病情信息及各凝血指标分布情况,并根据血瘀证诊断标准分为血瘀证组和非血瘀证组,①分析血瘀证患者在非小细胞肺癌患者中的构成比及证候分布特点。②分析血瘀证与一般资料、病理类型、ECOG(Ea stern CooperativeOncology group,ECOG)评分、肿瘤分期、各证型及血凝指标APTT(activatedpartial thrombopla stin time,APTT)、PT(prothrombin time,PT)、TT(thrombin time,TT)、Fbg(fibrinogen,Fbg)、D-二聚体(D-dimer,DD)之间的相关性。
结果①在我们所收集的257例中晚期非小细胞肺癌患者中,气虚、阴虚、痰湿及血瘀均是其临床常见证候,其中血瘀的构成比为72.37%;②在中晚期非小细胞肺癌各证候中,阴虚与血瘀的关系更为密切,在血瘀证患者中阴虚的构成比较非血瘀证患者明显增加;③在中晚期非小细胞肺癌中,血瘀证与年龄、性别、家族史、治疗经过等一般情况以及病理类型无明显相关性,而与肿瘤患者ECOG评分、肿瘤的分期具有一定联系,随着ECOG评分及分期的增加,血瘀证有增多的趋势;④与中晚期非小细胞肺癌非血瘀证相比较,血瘀证患者D-dimer明显升高,差异显著,在多因素逻辑回归分析中也显示出与血瘀证存在明显的正相关。
结论①血瘀证在中晚期非小细胞肺癌中普遍存在,相对于其他证候更为常见;②气虚、阴虚及痰湿作为肺癌的临床常见证候,被认为是影响中晚期非小细胞肺癌血瘀证的主要因素,但相对于非血瘀证,中晚期非小细胞肺癌血瘀证患者存在明显的阴虚致瘀的病理特点;③ECOG评分、肿瘤分期与中晚期非小细胞肺癌血瘀证具有一定的关联性,不仅反映了血瘀证与肿瘤的增殖与转移存在一定的联系,可作为判定中晚期非小细胞肺癌预后的重要因素,而且ECOG评分、肿瘤分期也可以在血瘀证的诊疗中为中医辨病提供参考;④D-dimer与血瘀证的强相关性,不仅反映了中晚期非小细胞肺癌血瘀证患者存在血液的高凝状态,而且还在一定程度上反映了中晚期非小细胞肺癌血瘀证在血凝功能异常方面的实质,并可成为非常实用的临床诊断血瘀证的微观指标;⑤根据中晚期非小细胞肺癌的证候特点及其与血瘀证之间的相关性,我们认为临床应以益气养阴、活血化痰作为中晚期非小细胞肺癌血瘀证的基本治疗策略,不仅体现了中医辨证论治的优势,也充分体现了与肿瘤治疗的统一性。
objective Through the retrospective clinical study,to investigate distribution regularity and characteristics of blood stasis syndrome in advanced non-small cell lung cancer and further to analyze the correlation between blood stasis syndrome and pathological types,tumor stage,haemostasis markers,combination syndromes etc,and then to provide reference for clinical treatment of blood stasis syndrome. Method We took the patients of advanced non-small cell lung cancer from Dong Zhi Mei hospital and Bei Jing hospital of traditional Chinese medicine(TCM) during the recent five years as study cases,and made investigation table,collected cases.Using descriptive analysis to recognize the distribution status of general materials,information of disease and every haemostasis markers,and according to the diagnostic criteria of blood stasis syndrome,these cases were divided into blood stasis syndrome group and non-blood stasis syndrome group.①to analyze the composition ratio and combination syndromes distribution characteristics of patients with blood stasis syndrome;②to analyze the correlation between blood stasis syndrome and general materials, pathological types,tumor stages,every combination syndromes, haemostasis marker APTT(activated partial thromboplastin time),PT (prothrombin time),TT(thrombin time),Fbg(fibrinogen),D-dimer.
Results①Among the collected 257 cases of advanced non-small cell lung cancer,Qi deficiency,yindeficiency,phlegm dampness and blood stasis were all common clinical syndromes,and composition ratio of blood stasis among these syndromes was 72.37%;②Among these syndromes of advanced non-small cell lung cancer,Yin deficiency had a tighter correlation with blood stasis than other syndromes,comparing with non-blood stasis syndrome composition ratio of Yin deficiency was significantly increased in blood stasis syndrome;③In advanced non-small cell lung cancer,blood stasis syndrome had no correlation with general materials of age,sex,family disease history,treatment experience etc and pathological types,but had some correlation with ECOG performance score and the staging of the tumor,with the increase of staging and ECOG score,blood stasis syndrome were with increasing trend;④Comparing with non-blood stasis syndrome of advanced non-small cell lung cancer,D-dimer level of patients with blood stasis syndrome was obviously increased with a significant difference,and also had a significant positive correlation with blood stasis syndrome in multifactor Logistic regression analysis.
Conclusion①In advanced non-small cell lung cancer,blood stasis syndrome was prevalent and more common than other syndromes;②Qi deficiency,yin deficiency and phlegm dampness,which were common syndromes of lung cancer in clinic,all were recognized as primary influencing factors of blood stasis syndrome,but comparing with non-blood stasis syndrome,there was an obvious pathological characteristic of yin deficiency causing blood stasis in blood stasis syndrome of advanced non-small cell lung cancer;③The correlation between ECOG score,tumor staging and blood stasis syndrome,not only reflected some links between blood stasis syndrome and tumor proliferation,matastasis,and thereby ECOG score and tumor staging may were taken to be as important factors for prognosis,but also ECOG score and tumor stage may also provide the basic foundation for disease differentiation of TCM in blood stasis syndrome diagnosis and treatment;④The significant correlation between D-dimer and blood stasis syndrome not only reflected tumor hypercoagulative status in the patients of blood stasis syndrome,but also,to some extent,reflected the blood stasis syndrome essentials of advanced non-small cell lung cancer in terms of blood coagulation disfunction,and then it may was very useful to be taken as a micro-index for clinical diagnosis of blood stasis syndrome;⑤According to the characteristics of blood stasis syndrome combination syndromes and its correlation with blood stasis syndrome, we consider that strengthening qi and nurishing yin,activating blood and removing phlegm should be the basic strategy for the treatment of blood stasis syndrome of advanced non-small cell lung cancer,it not only embodieded the advantage of treatment based on syndrome differentiation of TCM,but also embodied the unity with tumor therapy.
引文
1.Gouin-Thibault I,Samama MM.Laboratory diagnosis of the thrombophilic state in cancer patients[J].Clin Adv Hematol Oncol,2003,1(11): 668-671.
2.Lip GY,Chin BS,Blann AD,et al.Cancer and the prothrombotic state[J]Lancet Oncol,2002,3(1):27-34.
3.汤依群,钱明珍,陈建文,等.恶性肿瘤患者血流变学的检测及分析[J].淮海医学,2001,19(2):139-140.
4.黄敏,谭平.老年恶性肿瘤血液流变性及血小板的变化[J].微循环学杂志,2006,16(3):51-52.
5.田斌,田忠.正常人与肿瘤患者血液流变学微循环数字成像半定量分析比较[J].中国现代普通外科进展,2006,9(6):375-376.
6.胡庆福,陈泽霖,陈依萍,等.血瘀型恶性肿瘤病人红细胞膜流动性及血流变性观察[J].肿瘤,1990,10(4):174-175.
7.黄瑞文,刘华强,李勇.支气管肺癌患者甲袭微循环状态检测结果的分析[J].临床肿瘤学杂志,2001,6(1):70-71.
8.赵付芝,李庆云.消化道恶性肿瘤患者的甲皱微循环观察[J].山东医药,2002,42(18);42-43.
9.陈泽民,李泽浩,江建平,等.肝癌病人舌质与微循环的关系-附100例临床分析[J].中西医结合肝病杂志,1999,9(3):44-45.
10.Dvorak HF,Nagy JA,Berse B,et al.Vascular permeability factor,fibrin,and the pathogenesis of tumor stroma formation[M].Ann NY Acad Sci,1992,667:101-111.
11.Gordon SG,Cross BA.An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as a new tumor marker[J].Cancer Res,1990,50(19):6229-6234.
12.Mielicki WP,Gordon SG.Three stage chromogenic assay for the analysis of activation properties of factor X by cancer procoagulant [J].Blood Coagul Fibrinolysis,1993,4(3):441-446.
13.Gale AJ,Gordon SG.Update on tumor cell onprocaugulant factors[J].Acta Haematol,2001,106(1-2):25-32.
14.Guan M,Jin J.Tissue factors expression and angiogenesis in human glioma[J],Clin Biochem,2002,35(4):321-325.
15.Nitori N,Ino Y,Nakanishi Y,et al.Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma[J].Clin Cancer Res,2005,11(7):2531-2539.
16.Donati MB,Lorenzet R.Coagulation factors and tumor cell biology;the role of tissue fator[J].Pathophsio haemost thromb,2003,33(supple 1):22-25.
17.Nemerson Y.The tissue factor pathway of blood coagulation[J].Semin Haematol[J],1992,29(3):170-176.
18.Olas B,Wachowicz B,Mielicki WP.Cancer procoagulant and blood platelet activation[J].Cancer Lett,2001,169(2):165-171.
19.Hara Y,Steiner M,Baldini MG.Caracterization of the platelet aggregating activity of tumour cells[J].Cancer Res,1980,40(4):1217-1222.
20.Gasic,GJ.Gasic,TB.Stewart,GJ.Mechanisms of platelet aggregation by murine tumor cell shedding[N].In:Honn KV,Sloane BF.editors.Hemostatic Mechanisms and Metastases.Boston:Martinus Nijhoff,1984,pp:127-138.
21.Wojtukiewicz MZ,Sierko E,Zacharski LR,et al.Tissue factor-dependent coaugulation activiation and impaired fibrinolysis in gastric cancer[J].Semin Thromb Hemost,2003,29(3):291-299.
22.Gabazza EC,Taguchi O,Yamakami r,Machishi M,Ibata H,Suzuki S,Shima T.Ateration of coagulation and fibrinolysis systems after muttidrug anticancer therapy for lung cancer[J].Eur J cancer,1994,30(9):1276-1281.
23.陈芳,宁琴,等.恶性肿瘤组织中人纤维介素的表达及作用[J].华中科技大学学报,2006,8(35):444-448.
24.Colluci M,Balconi G,Lorenzet R,Pietra A,Locati D,Donati MB,Semeraro N.Cultured human endothelial cells generate tissue factor in response to endotoxin[J].J Clin Invest,1983,71(6):1893-1896.
25.Bevilacqua MP,Pober JS,Majeau GR,etal.Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium:characterization and comparison with the actions of interleukin-1.Proc Natl Acad Sci USA.1986,83(12):4533-4537.
26.Dittman WA,Majerus PW.Structure and function of thrombomodulin:a natural anticoagulant.Blood,1990,75(2):329-336.
27.黄松音,段朝晖,梁穆兴,等.肿瘤患者凝血指标变化的临床意义[J].血栓与止血杂志,2002,8(4):156.
28.林粤,韩玲霞.恶性肿瘤患者凝血指标测定的临床评价[J].现代中西医结合杂志,2006,15(5):636-637.
29.Rickles,FR,Edwards,RL,Barb C,Cronlund M.Abnormalities of blood coagulation in patients with cancer fibrinopeptied A generation and tumor growth[J].Cancer,1983,51(2):301-307.
30.赵建荣,张开资.恶性肿瘤患者不同阶段凝血功能及血小板变化分析.华北煤炭学院学报,2006,8(1):84-85.
31.徐成伟,王芳,吴文秀,等.肿瘤患者凝血及纤溶状态的改变[J].齐鲁医学检验,2003,14(3):10-11.
32.Unsal E,Atalay F,Atikcn S,Yilmaz A.Prognostic significance of hemostatic parameters in patients with lung cancer[J].Respir Med,2004,98(2):93-98.
33.Milanini Mongiat J,Pouyssegur J,Pages G.Identification of two Spl phosphorylation sites for p42 /p44 mitogen-activated protein kinases:their implication in vascular endothelial growth factor gene transcription[J].J Biol Chem,2002,277(3):20631-20639.
34.Berra E,Milanini J,Richard DE,et al.Signaling angiogenesis via p42/p44 MAP kinase and hypoxia[J].Biochem Pharmacol,2000;60(3):1171-1178.
35.Karpatkin S.Does hypercoagulability awaken dormant tumor cells in the host?[J].J Thromb Haemost,2004,2(12):2103-2106.
36.Yin YJ,Salah Z,Grisaru-Granovsky S,Cohen I,Cohen Even-Ram S,Maoz M,Uziely B,Bar-Shavit R.Human protease-activated receptor 1expression in malignant epithelia:a role in invasiveness[J]. Arterioscler Thromb Vase Biol,2003,23 (26):940-944.
37.Bogatcheva NV,Garcia JG,Verin AD.Molecular mechanisms of thrombin induced endothelial cell permeability[J].Biochemistry(Mosc),2002,67 (1):75-84.
38.Tsopanoglou NE,MaragoudakisME.Role of thrombin in angiogenesis and tumor progression[J].Semin Thromb Hemost,2004,30 (1):63-69.
39.Rickles FR,Patierno S,Fernandez PM.Tissue factor,thrombin,and cancer[J].Chest,2003,124 (Supp 13):58s-68s.
40.NaldiniA,CarneyDH,PucciA,et al.Thrombin regulates the expression of proangiogenic cytokines via p roteolytic activation of protease ctivated receptor[J].Gen Pharmacol,2000,35 (5):255-259.
41.Black PC,Mize GJ,Karl in P,Greenberg DL,Hawley SJ,True LD,Vessel la RL,Takayama TK.Overexpress ion of protease-act ivated receptors-1,-2,and-4 (PAR-1,-2,and-4) in prostate cancer[J].Prostate,2007,67(7):743-756.
42.Massi D,Naldini A,Ardinghi C,Carraro F,Franchi A,Paglierani M,Tarantini F,Ketabchi S,Cirino G,Hollenberg MD,Geppetti P,Santucci M.Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma[J].Hum Pathol,2005,36 (6):676-685.
43.Darmoul D,Grat io V,Devaud H,Lehy T,Laburthe M.Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells[J].Am J Pathol,2003,162 (5):1503-1513.
44.Depasquale I,Thormpson.Prognosis in human melanoma:PAR-1 expression is superior to other coagulation components and VEGF[J].Histopathology,2008,52 (4):500-509.
45.Ahan I,Fujimoto J,Alam SM,Sato E,Sakaguchi H,Tamaya T.Role of protease activated receptor-2 in tumor advancement of ovarian cancers[J].Ann Oncol,2007,18 (9):1506-1512.
46.Coughlin SR.Thrombin signalling and protease-activated receptors[J].Nature,2000,407(6801):258-264.
47.Ruf W,Dorfleutner A,Riewald M.Specificity of coagulation factor signaling[J].J Thromb Haemost,2003,1(7):1495-1503.
48.汤坚强,万远廉,刘玉村等.组织因子促进人类大肠癌细胞的侵袭及与基质金属蛋白酶的相关性研究[J].北京大学学报(医学版),2005,37(3):265-268.
49.成春英,王建钧,文志斌.组织因子/凝血因子VⅡa与肿瘤[J].中国医师杂志,2006,8(7):107-108.
50.Goldin-Lang P,Tran QV,Fichtner I,etal.Tissues indicate increased blood thrombogenicity and tumor metastasis[J].Oncol Rep,2008,20(1):123-128.
51.patry G,Hovington H,Larue H,Harel F,Fradet Y,LacombeL.Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer[J].Int J Cancer,2008,122(7):1592-1597.
52.Bobek V,lovarik J.Antitumor and antimetastatic effect of warfarin and heparin[J].Biomed Pharmacother,2004,58(4):213-219.
53.Balzarotti M,Fontana F,Marras C,Boiardi A,Croci D,Ciusani E,Salmaggi A.In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas[J].Oncol Res,2006,16(5):245-250.
54.陈培丰,刘鲁明,陈晨,等.恶性肿瘤肝转移血瘀证与参三七、丹参干预作用的研究[J].浙江中医药大学学报,2007,31(5):552-553.
55.薛松,朱成全,肖烈钢.加味四君固本汤对恶性肿瘤患者血液流变性和甲襞微循环的影响[J].安徽中医学院学报,2006,25(5):9-10.
56.顾小侠,刘书林,陶玉华.参麦合葛根注射液改善恶性肿瘤高凝状态45例观察[J].浙江中医杂志,2005,40(9):413-414.
57.毕宏观,王俊茹,张柯楠,等.参麦注射液对恶性肿瘤患者血液流变性及微循环的影响[J].中国医学物理学杂志,2005,22(5):675-676.
58.缪旭东,管卫群.参附注射液对中晚期恶性肿瘤患者微循环及血液流变性的影响[J].中国微循环,2004,8(3):185-186.
59.林洪生,李树奇,裴迎霞,等.川芎嗪、苦参碱对癌细胞与内皮细胞黏附及黏附因子表达的影响[J].中国新药杂志,1999,8(6):384-385.
60.孙婧,周信达,刘银坤.丹参对肝癌复发防治作用的研究[J].中国中西医结合杂志,1999,19(5):292-295.
61.陈少贤,王良兴,刑玲玲,等.川芎嗪对晚期肺癌血小板功能的影响[J].中国中西医结合杂志,1997,17(9):531-533.
62.傅乃武,范贤骏,王永泉,等.丹参对实验肿瘤生长和转移的影响及原理的初步探讨[J].中华肿瘤杂志,1981,3(3):165-166.
63.丁罡,宋明志,于尔辛,等1丹参、赤芍对大鼠walker256癌肝转移影响机制的研究[J].中国癌症杂志,2001,11(4):364-366.
64.徐德成,张培宇.活血化瘀强度与气血双亏型胃癌转移率相关性机理探讨[J].中医杂志,1998,39(3):156-157.
65.韩晓红,石远凯,冯奉仪,等.流式细胞术分析肿瘤患者免疫功能变化[J].实用肿瘤杂志,1999,14(5):273-275.
66.黄海茵,于尔辛.中药对NK、LAK细胞及IL-2活性的影响[J].中国中西医结合杂志,1993,13(4):253-255.
67.刘嘉湘,施志明,赵丽红,等.正得康在癌症治疗中扶正作用的研究[J].中医药学刊,2001,19(5):423-425.
68.魏影非,杜惠兰,王素云,等.参附注射液配合化疗治疗急性白血病疗效及对细胞免疫、血清IL-6和TNF-α水平的影响[J].中国中西医结合杂志,2003,23(4):258-260.
69.骆丽娟.扶正合剂防治药物性骨髓毒性的疗效观察[J].辽宁中医杂志,2001,28(1):27-28.
70.ZhangW,Chuang YJ,Swanson R,et al.Antiangiogenic antithrombin downregulates the expression of the proangiogenic heparan sulfate proteoglycan,perlecan,in endothelial cells[J].Blood,2004,103(4):1185-1191.
71.Arora P,Cuevas BD,Russo A,etal.Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion[J].Oncogene,2008,27(32):4434-4445.
72.Hembrough TA,Swartz GM,Papathanassiu A,et al.Tissue factor/ factor Vila inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism[J].Cancer Res,003,63(11):2997-3000.
73.Versteeg HH,Schaffner F,Kerver M,etal.Inhibit ion of tissue factor signaling suppresses tumor growth[J].Blood,2008,111(1):190-199.
74.Verstereeg HH,Spek CA,Reppelenbosch MP,etal.Tissue factor and cancer metastasis the role of intracellular and extracellular signaling pathways[J].Mol Med,2004,10(16):6-11.
75.Hu ZW,Garen A.Targeting tissue factor on tumor vascular endothelial eel Is and tumor eel Is for immunotherapy in mouse models of pros tat ic cancer[J].PNAS,2001,98(21):12180-12185.
76.Hu ZW,Garen A.Intratumoral injection of adenoviral vectors encoding tumor targeted immunoconjugates for cancer immunotherapy[J].PNAS,2000,97(16):9221-9225.
77.Amirkhosravi A,Meyer T,Amaya M,Davila M,Mousa SA,Robson T,Francis JL.The role of tissue factor pathway inhibitor in tumor growth and matastasis[J].Semin Thromb hemost,2007,33(7):643-652.
1.Shtherland DE,Wetitz IC,Liebman HA.Thromboembolic complications of cancer:epidemiology,Pathogenesis,diagnosis,and treantment [J].Am J Hematol,2003,72(1):43-52.
2.L(?)pez JA,Kearon C,Lee AYY.Deepvenous thrombosis(M).Am Soc Hematol Educational Book,2004,439-456.
3.Lip GY,Chin BSP,Blam AO.Cancer and the prothrombolic state[J].Lancet Oncol,2002,3(1):27-34.
4.Goldhaber SZ,Tapson VF.A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis[J].Am J Cardiol,2004,93(2):259-262.
5.Blom JW,Doggen CJ,Osanto S,Rosendaal FR.Malignancies,prothrombotic mutations,and the risk of venous thrombosis[J].JAMA,2005,293(6):715-722.
6.Thodiyil PA,Kakkar AK.Variation in relative risk of venous thromboembolism in different cancers[J].Thromb Haemost,2002,87(6):1076-1077.
7.Lugassy G,Fanlanga A,Kakkar A,et al.Thrombosis and cancer(M). Taylor &Francis,2004,117-127.
8.Gordon LI,Kwaan HC.Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura /hemolytic uremic syndrome in the cancerpatients[J].Semin Thromb Hemost,1999,25(2):217-221.
9.Karen BG,Roy LS.Hypercoagulability in cancer[J].Hematol Oncol Clin North Am,1996,10(2):499-530.
10.John LF,John B,Ali A.Hemostasis and malignancy[J].Seminars in Thrombosis and Hemostasis,1998,24 (2):93-109.
11.Otten HM,Mathijssen J,Cate,HT,et al.Symptomatic venous thromboembosis in cancer patients treated with chemotherapy:An underestimated phenomenon[J].Arch Inter Med,2004,164 (2):190-194.
12.Shah MA,II son D,Ke Is en DP.Thromboembol ic event in gastric cancer:High incidence in patients receiving irinotecan-and bevacizumabbased therapy[J].J Clin Oncol,2005,23(11):2574-2576.
13.Numico G,Garrone 0,Dongiovanni V,et al.Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine[J].Cancer,2 005,103 (5):994-999.
14.Cushman M,Costantino JP,Bovill EG et al.Effect of tamoxifen on venous thrombosis risk factors in women without cancer:the Breast Cancer Prevention Trial[J].Br J Haematol 2003,120(1):109-116.
15.Bohlius J.Wilson J,Seidenfeld J,et al.Recombinant human erythropoietins and cancer paients:updated meta-analysis of 57 studies including 9353 patients[J].J Natl Cancer inst,2006,98 (10):708-714.
16.Rosenzweig MQ,Bender CM,Lucke JP,et al.The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events[J].J Pain Symptom Manage,2004,27(2):185-190.
17.Hurwitz H,Fehrenbacher L,Novotny W,et al.Bevacizumab plus irinotecan,fluorouracil,and leucovorin for metastatic colorectal cancer[J].N Eng J Med,2004,350 (23):2335-2342.
18.Shah MA,I Is on D,Kelsen DP.Thromboembol ic event in gastric cancer:High incidence in patients receiving irinotecan-and bevacizumab-based therapy[J].J Clin Oncol,2005,23(11):2574-2576.
19.Zangari M,Anaissie E,Barlogie B,Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy[J],blood,2001,98 (5):1614-1615.
20.Mitchell LG,Andrew M,Hanna K,et al:A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase:Results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA)study[J].Cancer,2003,97(2):508-516.
21.Verso M,Agnelli G.Venous thromboembolism associated with longterm use of central venous catheters in cancer patients[J].J Clin Oncol,2003,21(19):3665-3675.
22.Male C,Chait P,Andrew M,et al.Central venous line related thrombosis in children association with central venous line location and insertion technique[J].Blood,2003;101 (11):4273-4278.
23.Bergqvist D,Agnelli G,Cohen AT,et al.Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer[J].N Engl J Med,2002,346:975-980.
24.Rasmussen MS.Preventing thromboembolic complications in cancer patients after surgery:A role for prolonged thromboprophylaxis[J].Cancer Treatment Rev,2002,28 (3):141-144.
25.Levine M,Hirsh J,Gent M,et al.Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer[J].Lancet,1994,359 (4):886-889.
26.Karen BG,Roy LS.Hypercoagulability in cancer[J].Hematol Oncol Clin North Am,1996,10 (2):499-530.
27.Levine MN.Managing thromboembolic disease in the cancer patients:efficacy and safety of antithrombotic treatment options in patients with cancer[J].Cancer Treat Rev,2002,28 (3):145-149.
28.Thodiyil P,Kakkar AK.Can low2molecular2weight heparins improve outcome in patients with cancer ?[J].Cancer Treat Rev,2002,28 (3):151-155.
29.Hutten BA,Prins MH,Gent M,et al.Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio:a retrospective analysis[J].J Clin Oncol,2000,18(17):3078-3083.
30.Buller H R,Agnelli G,Hull R,et al.Antit hrombotic t herapy forvenous thromboembolic disease:the Seventh.ACCP Conferenceon Antithrombotic and ThrombolyticTherapy[J].Chest,2004,126 (Suppl 3):401-428.
31.Deitcher S R.Cancer2related deep venous thrombosis:clinical importance,treatment challenges,and management strategies[J].Semin Throm b Hemost,2003,29 (3):247-258.
32.Decousus H,Leizorovicz A,Parent F.A clinical trial of venacaval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis[J].N Eng J Med,1998,338(7):409-415.
33.Prandoni P,Piccioli A.Venous thromboembolism and cancer:A twoway clinical association[J].Front Biosc,1997,2:el2—20.
1.Gouin-Thibault I,Samama MM.Laboratory diagnosis of the thrombophilic state in cancer patients[J].Clin Adv Hematol Oncol,2003,1(11):668-671.
2.Lip GY,Chin BS,Blann AD,et al.Cancer and the prothrombotic state[J].Lancet Oncol,2002,3(1):27-34.
3.何瑞芝.丹参的药理作用及其临床应用[J].云南医药,1986,7(4):242-243.
4.郑大为,栾杰男.碟脉灵注射液对血瘀证治疗前后血液流变学观察[J].医药世界,2006,11(2):27-28.
5.中国抗癌协会.新编常见恶性肿瘤诊治规范(第九分册)-原发性支气管肺癌[M].北京:中国协和医科大学出版社,1999.773-781.
6.孙燕,石远凯.临床肿瘤内科手册[M].人民卫生出版社,2007,399-401.
7.沈自尹,王文健.中医虚证辨证参考标准[J].中西医结合杂志,1986,6(10):598.
8.朱文锋.中医诊断学[M].上海科技出版社,2005.
9.王永炎.中医内科学.[M].1994.
10.程绍恩,夏洪生.中医证候诊断治疗学[M].北京:科学技术出版社,1993.
11.王阶,姚魁武.血瘀证诊断标准研究述要及思考[J].中国中医药信息杂志,2004,11(1):17-19.
12.国家技术监督局.中医临床诊疗术语[M].北京:中国标准出版社,1997.
13.胡小梅,张培彤,杨宗艳,等.中晚期非小细胞肺癌患者中医证型分布规律研究[J].中国肿瘤,2007,16(1):51-52.
14.候丽,姜苗,陈信义,等.晚期非小细胞肺癌中医证候特征回顾性临床研究[J].中国中医药信息杂志,14(4):19-20.
15.齐清会.腹部手术后和重症急腹症患者胃阴虚的研究[J].中西医结合杂志,1990,10(1):162.162-163.
16.胡庆福,陈泽霖,戴豪良,等.阴虚光剥舌形成机理的研究[J].中西医结合杂志,1989,9(3):153-154.
17.刘春秋.肺癌患者凝血状态变化的观察[J].河北医药,2007,29(9):929-930.
18.赵建荣,张开资.恶性肿瘤患者不同阶段凝血功能及血小板变化分析[J].华北煤炭学院学报,2006,8(1):84-85.
19.徐成伟,王芳,吴文秀等.肿瘤患者凝血及纤溶状态的改变[J].齐鲁医学检验,2003,14(3):10-11.
20.Unsal E,Atalay F,Atikcn S,Yilmaz A.Prognostic significance of hemostatic parameters in patients with lung cancer[J].Respir Med,2004,98(2):93-98.
21.Piccioli A,Prandoni P,Ewenstein BM,et al.Cancer and venous thromboembolism[J].Am Heart J,1996,132(4):850-855.
22.田斌,田忠.正常人与肿瘤患者血液流变学微循环数字成像半定量分析比较[J].中国现代普通外科进展,2006,9(6):375-376.
23.Nitori N,Ino Y,Nakanishi Y,et al.Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma[J].Clin Cancer Res,2005,11(7):2531-2539.
24.Donati MB,Lorenzet R.Coagulation factors and tumor cell biology;the role of tissue fator[J].Pathophsio haemost thromb.2003,33(supple 1):22-25.
25.Wojtukiewicz MZ,Sierko E,Zacharski LR,et al.Tissue factor-dependent coaugulation activiation and impaired fibrinolysis in gastric cancer[J].Semin Thromb Hemost,2003,29(3):291-299.
26.Monreal M,Prandoni P.Venous thromboembolism as first manifestation of cancer[J].Seminars in Thrombosis and Hemastasis,1999,25(2):131-135.
27.薛松,朱成全,肖烈钢.加味四君固本汤对恶性肿瘤患者血液流变性和甲襞微循环的影响[J].安徽中医学院学报,2006,25(5):9-10.
28.顾小侠,刘书林,陶玉华.参麦合葛根注射液改善恶性肿瘤高凝状态45例观察[J].浙江中医杂志,2005,40(9):413.
29.罗长义.益气养阴抗肿瘤的动物实验研究[J].甘肃中医,1999,12(4):51-54.3
0.孙慧莉,施志明,赵丽红,等.益气养阴方对中晚期原发性非小细胞肺癌患者免疫功能的影响[J].中医药临床杂志,2005,17(5):474-475.
31.刘鲁明,吴良村,林胜友,等.参麦注射液对非小细胞肺癌化疗减毒作用[J].浙江中西医结合杂志,2000,10(6):322-323.
32.丁罡,宋明志,于尔辛,等1丹参、赤芍对大鼠walker256癌肝转移影响机制的研究[J].中国癌症杂志,2001,11(4):364-366.
33.徐德成,张培宇.活血化瘀强度与气血双亏型胃癌转移率相关性机理探讨[J].中医杂志,1998,39(3):156-157.
34.李道睿,张培彤,胡晓梅,等.300例中晚期原发性支气管肺癌血瘀证分布规律的调查研究[J].中国中医药信息杂志,2007,14(3):19-21.
35.陈泽民,李泽浩,江建平,等.肝癌病人舌质与微循环的关系-附100例临床分析(J].中西医结合肝病杂志,1999,9(3):44-45.
36.Milanini Mongiat J,Pouyssegur J,Pages G.Identification of two Spl phosphorylation sites for p42 /p44 mitogen-activated protein kinases:their implication in vascular endothelial growth factor gene transcription[J].J Biol Chem,2002,277(3):20631-20639.
37.Berra E,Milanini J,Richard DE,et al.Signaling angiogenesis via p42 /p44 MaP kinase and hypoxia[J].Biochem Pharmacol,2000,60(8):1171-1178.
38.Bogatcheva NV,Garcia JG,Verin AD.Molecular mechanisms of thrombin induced endothelial cell permeability[J].Biochemistry(Mosc),2002,67(1):75-84.
39.Karpatkin S.Does hypercoagulability awaken dormant tumor cells in the host? J Thromb Haemost[J],2004,2(12):2103-2106.
40.Yin YJ,Salah Z,Grisaru-Granovsky S,Cohen I,Cohen Even-Ram S,Maoz M,Uziely B,Bar-Shavit R.Human protease-activated receptor 1 expression in malignant epithelia:a role in invasiveness[J].Arterioscler Thromb Vasc Biol,2003,23(6):940-944.
41.Tsopanoglou NE,MaragoudakisME.Role of thrombin in angiogenesis and tumor progression[J].Semin Thromb Hemost,2004,30(1):63-69.
42.Rickles FR,Patierno S,Fernandez PM.Tissue factor,thrombin,and cancer[J].Chest,2003,124(Supp-13):58S-68s.
43.Ruf W,Dorfleutner A,Riewald M.Specificity of coagulation factor signaling.J Thromb Haemost[J],2003,1(7):1495-1503.
44.汤坚强,万远廉,刘玉村,等.组织因子促进人类大肠癌细胞的侵袭及与基质金属蛋白酶的相关性研究[J].北京大学学报,2005,37(3):265-268.
2.Lip GY,Chin BS,Blann AD,et al.Cancer and the prothrombotic state[J]Lancet Oncol,2002,3(1):27-34.
3.汤依群,钱明珍,陈建文,等.恶性肿瘤患者血流变学的检测及分析[J].淮海医学,2001,19(2):139-140.
4.黄敏,谭平.老年恶性肿瘤血液流变性及血小板的变化[J].微循环学杂志,2006,16(3):51-52.
5.田斌,田忠.正常人与肿瘤患者血液流变学微循环数字成像半定量分析比较[J].中国现代普通外科进展,2006,9(6):375-376.
6.胡庆福,陈泽霖,陈依萍,等.血瘀型恶性肿瘤病人红细胞膜流动性及血流变性观察[J].肿瘤,1990,10(4):174-175.
7.黄瑞文,刘华强,李勇.支气管肺癌患者甲袭微循环状态检测结果的分析[J].临床肿瘤学杂志,2001,6(1):70-71.
8.赵付芝,李庆云.消化道恶性肿瘤患者的甲皱微循环观察[J].山东医药,2002,42(18);42-43.
9.陈泽民,李泽浩,江建平,等.肝癌病人舌质与微循环的关系-附100例临床分析[J].中西医结合肝病杂志,1999,9(3):44-45.
10.Dvorak HF,Nagy JA,Berse B,et al.Vascular permeability factor,fibrin,and the pathogenesis of tumor stroma formation[M].Ann NY Acad Sci,1992,667:101-111.
11.Gordon SG,Cross BA.An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as a new tumor marker[J].Cancer Res,1990,50(19):6229-6234.
12.Mielicki WP,Gordon SG.Three stage chromogenic assay for the analysis of activation properties of factor X by cancer procoagulant [J].Blood Coagul Fibrinolysis,1993,4(3):441-446.
13.Gale AJ,Gordon SG.Update on tumor cell onprocaugulant factors[J].Acta Haematol,2001,106(1-2):25-32.
14.Guan M,Jin J.Tissue factors expression and angiogenesis in human glioma[J],Clin Biochem,2002,35(4):321-325.
15.Nitori N,Ino Y,Nakanishi Y,et al.Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma[J].Clin Cancer Res,2005,11(7):2531-2539.
16.Donati MB,Lorenzet R.Coagulation factors and tumor cell biology;the role of tissue fator[J].Pathophsio haemost thromb,2003,33(supple 1):22-25.
17.Nemerson Y.The tissue factor pathway of blood coagulation[J].Semin Haematol[J],1992,29(3):170-176.
18.Olas B,Wachowicz B,Mielicki WP.Cancer procoagulant and blood platelet activation[J].Cancer Lett,2001,169(2):165-171.
19.Hara Y,Steiner M,Baldini MG.Caracterization of the platelet aggregating activity of tumour cells[J].Cancer Res,1980,40(4):1217-1222.
20.Gasic,GJ.Gasic,TB.Stewart,GJ.Mechanisms of platelet aggregation by murine tumor cell shedding[N].In:Honn KV,Sloane BF.editors.Hemostatic Mechanisms and Metastases.Boston:Martinus Nijhoff,1984,pp:127-138.
21.Wojtukiewicz MZ,Sierko E,Zacharski LR,et al.Tissue factor-dependent coaugulation activiation and impaired fibrinolysis in gastric cancer[J].Semin Thromb Hemost,2003,29(3):291-299.
22.Gabazza EC,Taguchi O,Yamakami r,Machishi M,Ibata H,Suzuki S,Shima T.Ateration of coagulation and fibrinolysis systems after muttidrug anticancer therapy for lung cancer[J].Eur J cancer,1994,30(9):1276-1281.
23.陈芳,宁琴,等.恶性肿瘤组织中人纤维介素的表达及作用[J].华中科技大学学报,2006,8(35):444-448.
24.Colluci M,Balconi G,Lorenzet R,Pietra A,Locati D,Donati MB,Semeraro N.Cultured human endothelial cells generate tissue factor in response to endotoxin[J].J Clin Invest,1983,71(6):1893-1896.
25.Bevilacqua MP,Pober JS,Majeau GR,etal.Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium:characterization and comparison with the actions of interleukin-1.Proc Natl Acad Sci USA.1986,83(12):4533-4537.
26.Dittman WA,Majerus PW.Structure and function of thrombomodulin:a natural anticoagulant.Blood,1990,75(2):329-336.
27.黄松音,段朝晖,梁穆兴,等.肿瘤患者凝血指标变化的临床意义[J].血栓与止血杂志,2002,8(4):156.
28.林粤,韩玲霞.恶性肿瘤患者凝血指标测定的临床评价[J].现代中西医结合杂志,2006,15(5):636-637.
29.Rickles,FR,Edwards,RL,Barb C,Cronlund M.Abnormalities of blood coagulation in patients with cancer fibrinopeptied A generation and tumor growth[J].Cancer,1983,51(2):301-307.
30.赵建荣,张开资.恶性肿瘤患者不同阶段凝血功能及血小板变化分析.华北煤炭学院学报,2006,8(1):84-85.
31.徐成伟,王芳,吴文秀,等.肿瘤患者凝血及纤溶状态的改变[J].齐鲁医学检验,2003,14(3):10-11.
32.Unsal E,Atalay F,Atikcn S,Yilmaz A.Prognostic significance of hemostatic parameters in patients with lung cancer[J].Respir Med,2004,98(2):93-98.
33.Milanini Mongiat J,Pouyssegur J,Pages G.Identification of two Spl phosphorylation sites for p42 /p44 mitogen-activated protein kinases:their implication in vascular endothelial growth factor gene transcription[J].J Biol Chem,2002,277(3):20631-20639.
34.Berra E,Milanini J,Richard DE,et al.Signaling angiogenesis via p42/p44 MAP kinase and hypoxia[J].Biochem Pharmacol,2000;60(3):1171-1178.
35.Karpatkin S.Does hypercoagulability awaken dormant tumor cells in the host?[J].J Thromb Haemost,2004,2(12):2103-2106.
36.Yin YJ,Salah Z,Grisaru-Granovsky S,Cohen I,Cohen Even-Ram S,Maoz M,Uziely B,Bar-Shavit R.Human protease-activated receptor 1expression in malignant epithelia:a role in invasiveness[J]. Arterioscler Thromb Vase Biol,2003,23 (26):940-944.
37.Bogatcheva NV,Garcia JG,Verin AD.Molecular mechanisms of thrombin induced endothelial cell permeability[J].Biochemistry(Mosc),2002,67 (1):75-84.
38.Tsopanoglou NE,MaragoudakisME.Role of thrombin in angiogenesis and tumor progression[J].Semin Thromb Hemost,2004,30 (1):63-69.
39.Rickles FR,Patierno S,Fernandez PM.Tissue factor,thrombin,and cancer[J].Chest,2003,124 (Supp 13):58s-68s.
40.NaldiniA,CarneyDH,PucciA,et al.Thrombin regulates the expression of proangiogenic cytokines via p roteolytic activation of protease ctivated receptor[J].Gen Pharmacol,2000,35 (5):255-259.
41.Black PC,Mize GJ,Karl in P,Greenberg DL,Hawley SJ,True LD,Vessel la RL,Takayama TK.Overexpress ion of protease-act ivated receptors-1,-2,and-4 (PAR-1,-2,and-4) in prostate cancer[J].Prostate,2007,67(7):743-756.
42.Massi D,Naldini A,Ardinghi C,Carraro F,Franchi A,Paglierani M,Tarantini F,Ketabchi S,Cirino G,Hollenberg MD,Geppetti P,Santucci M.Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma[J].Hum Pathol,2005,36 (6):676-685.
43.Darmoul D,Grat io V,Devaud H,Lehy T,Laburthe M.Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells[J].Am J Pathol,2003,162 (5):1503-1513.
44.Depasquale I,Thormpson.Prognosis in human melanoma:PAR-1 expression is superior to other coagulation components and VEGF[J].Histopathology,2008,52 (4):500-509.
45.Ahan I,Fujimoto J,Alam SM,Sato E,Sakaguchi H,Tamaya T.Role of protease activated receptor-2 in tumor advancement of ovarian cancers[J].Ann Oncol,2007,18 (9):1506-1512.
46.Coughlin SR.Thrombin signalling and protease-activated receptors[J].Nature,2000,407(6801):258-264.
47.Ruf W,Dorfleutner A,Riewald M.Specificity of coagulation factor signaling[J].J Thromb Haemost,2003,1(7):1495-1503.
48.汤坚强,万远廉,刘玉村等.组织因子促进人类大肠癌细胞的侵袭及与基质金属蛋白酶的相关性研究[J].北京大学学报(医学版),2005,37(3):265-268.
49.成春英,王建钧,文志斌.组织因子/凝血因子VⅡa与肿瘤[J].中国医师杂志,2006,8(7):107-108.
50.Goldin-Lang P,Tran QV,Fichtner I,etal.Tissues indicate increased blood thrombogenicity and tumor metastasis[J].Oncol Rep,2008,20(1):123-128.
51.patry G,Hovington H,Larue H,Harel F,Fradet Y,LacombeL.Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer[J].Int J Cancer,2008,122(7):1592-1597.
52.Bobek V,lovarik J.Antitumor and antimetastatic effect of warfarin and heparin[J].Biomed Pharmacother,2004,58(4):213-219.
53.Balzarotti M,Fontana F,Marras C,Boiardi A,Croci D,Ciusani E,Salmaggi A.In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas[J].Oncol Res,2006,16(5):245-250.
54.陈培丰,刘鲁明,陈晨,等.恶性肿瘤肝转移血瘀证与参三七、丹参干预作用的研究[J].浙江中医药大学学报,2007,31(5):552-553.
55.薛松,朱成全,肖烈钢.加味四君固本汤对恶性肿瘤患者血液流变性和甲襞微循环的影响[J].安徽中医学院学报,2006,25(5):9-10.
56.顾小侠,刘书林,陶玉华.参麦合葛根注射液改善恶性肿瘤高凝状态45例观察[J].浙江中医杂志,2005,40(9):413-414.
57.毕宏观,王俊茹,张柯楠,等.参麦注射液对恶性肿瘤患者血液流变性及微循环的影响[J].中国医学物理学杂志,2005,22(5):675-676.
58.缪旭东,管卫群.参附注射液对中晚期恶性肿瘤患者微循环及血液流变性的影响[J].中国微循环,2004,8(3):185-186.
59.林洪生,李树奇,裴迎霞,等.川芎嗪、苦参碱对癌细胞与内皮细胞黏附及黏附因子表达的影响[J].中国新药杂志,1999,8(6):384-385.
60.孙婧,周信达,刘银坤.丹参对肝癌复发防治作用的研究[J].中国中西医结合杂志,1999,19(5):292-295.
61.陈少贤,王良兴,刑玲玲,等.川芎嗪对晚期肺癌血小板功能的影响[J].中国中西医结合杂志,1997,17(9):531-533.
62.傅乃武,范贤骏,王永泉,等.丹参对实验肿瘤生长和转移的影响及原理的初步探讨[J].中华肿瘤杂志,1981,3(3):165-166.
63.丁罡,宋明志,于尔辛,等1丹参、赤芍对大鼠walker256癌肝转移影响机制的研究[J].中国癌症杂志,2001,11(4):364-366.
64.徐德成,张培宇.活血化瘀强度与气血双亏型胃癌转移率相关性机理探讨[J].中医杂志,1998,39(3):156-157.
65.韩晓红,石远凯,冯奉仪,等.流式细胞术分析肿瘤患者免疫功能变化[J].实用肿瘤杂志,1999,14(5):273-275.
66.黄海茵,于尔辛.中药对NK、LAK细胞及IL-2活性的影响[J].中国中西医结合杂志,1993,13(4):253-255.
67.刘嘉湘,施志明,赵丽红,等.正得康在癌症治疗中扶正作用的研究[J].中医药学刊,2001,19(5):423-425.
68.魏影非,杜惠兰,王素云,等.参附注射液配合化疗治疗急性白血病疗效及对细胞免疫、血清IL-6和TNF-α水平的影响[J].中国中西医结合杂志,2003,23(4):258-260.
69.骆丽娟.扶正合剂防治药物性骨髓毒性的疗效观察[J].辽宁中医杂志,2001,28(1):27-28.
70.ZhangW,Chuang YJ,Swanson R,et al.Antiangiogenic antithrombin downregulates the expression of the proangiogenic heparan sulfate proteoglycan,perlecan,in endothelial cells[J].Blood,2004,103(4):1185-1191.
71.Arora P,Cuevas BD,Russo A,etal.Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion[J].Oncogene,2008,27(32):4434-4445.
72.Hembrough TA,Swartz GM,Papathanassiu A,et al.Tissue factor/ factor Vila inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism[J].Cancer Res,003,63(11):2997-3000.
73.Versteeg HH,Schaffner F,Kerver M,etal.Inhibit ion of tissue factor signaling suppresses tumor growth[J].Blood,2008,111(1):190-199.
74.Verstereeg HH,Spek CA,Reppelenbosch MP,etal.Tissue factor and cancer metastasis the role of intracellular and extracellular signaling pathways[J].Mol Med,2004,10(16):6-11.
75.Hu ZW,Garen A.Targeting tissue factor on tumor vascular endothelial eel Is and tumor eel Is for immunotherapy in mouse models of pros tat ic cancer[J].PNAS,2001,98(21):12180-12185.
76.Hu ZW,Garen A.Intratumoral injection of adenoviral vectors encoding tumor targeted immunoconjugates for cancer immunotherapy[J].PNAS,2000,97(16):9221-9225.
77.Amirkhosravi A,Meyer T,Amaya M,Davila M,Mousa SA,Robson T,Francis JL.The role of tissue factor pathway inhibitor in tumor growth and matastasis[J].Semin Thromb hemost,2007,33(7):643-652.
1.Shtherland DE,Wetitz IC,Liebman HA.Thromboembolic complications of cancer:epidemiology,Pathogenesis,diagnosis,and treantment [J].Am J Hematol,2003,72(1):43-52.
2.L(?)pez JA,Kearon C,Lee AYY.Deepvenous thrombosis(M).Am Soc Hematol Educational Book,2004,439-456.
3.Lip GY,Chin BSP,Blam AO.Cancer and the prothrombolic state[J].Lancet Oncol,2002,3(1):27-34.
4.Goldhaber SZ,Tapson VF.A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis[J].Am J Cardiol,2004,93(2):259-262.
5.Blom JW,Doggen CJ,Osanto S,Rosendaal FR.Malignancies,prothrombotic mutations,and the risk of venous thrombosis[J].JAMA,2005,293(6):715-722.
6.Thodiyil PA,Kakkar AK.Variation in relative risk of venous thromboembolism in different cancers[J].Thromb Haemost,2002,87(6):1076-1077.
7.Lugassy G,Fanlanga A,Kakkar A,et al.Thrombosis and cancer(M). Taylor &Francis,2004,117-127.
8.Gordon LI,Kwaan HC.Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura /hemolytic uremic syndrome in the cancerpatients[J].Semin Thromb Hemost,1999,25(2):217-221.
9.Karen BG,Roy LS.Hypercoagulability in cancer[J].Hematol Oncol Clin North Am,1996,10(2):499-530.
10.John LF,John B,Ali A.Hemostasis and malignancy[J].Seminars in Thrombosis and Hemostasis,1998,24 (2):93-109.
11.Otten HM,Mathijssen J,Cate,HT,et al.Symptomatic venous thromboembosis in cancer patients treated with chemotherapy:An underestimated phenomenon[J].Arch Inter Med,2004,164 (2):190-194.
12.Shah MA,II son D,Ke Is en DP.Thromboembol ic event in gastric cancer:High incidence in patients receiving irinotecan-and bevacizumabbased therapy[J].J Clin Oncol,2005,23(11):2574-2576.
13.Numico G,Garrone 0,Dongiovanni V,et al.Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine[J].Cancer,2 005,103 (5):994-999.
14.Cushman M,Costantino JP,Bovill EG et al.Effect of tamoxifen on venous thrombosis risk factors in women without cancer:the Breast Cancer Prevention Trial[J].Br J Haematol 2003,120(1):109-116.
15.Bohlius J.Wilson J,Seidenfeld J,et al.Recombinant human erythropoietins and cancer paients:updated meta-analysis of 57 studies including 9353 patients[J].J Natl Cancer inst,2006,98 (10):708-714.
16.Rosenzweig MQ,Bender CM,Lucke JP,et al.The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events[J].J Pain Symptom Manage,2004,27(2):185-190.
17.Hurwitz H,Fehrenbacher L,Novotny W,et al.Bevacizumab plus irinotecan,fluorouracil,and leucovorin for metastatic colorectal cancer[J].N Eng J Med,2004,350 (23):2335-2342.
18.Shah MA,I Is on D,Kelsen DP.Thromboembol ic event in gastric cancer:High incidence in patients receiving irinotecan-and bevacizumab-based therapy[J].J Clin Oncol,2005,23(11):2574-2576.
19.Zangari M,Anaissie E,Barlogie B,Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy[J],blood,2001,98 (5):1614-1615.
20.Mitchell LG,Andrew M,Hanna K,et al:A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase:Results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA)study[J].Cancer,2003,97(2):508-516.
21.Verso M,Agnelli G.Venous thromboembolism associated with longterm use of central venous catheters in cancer patients[J].J Clin Oncol,2003,21(19):3665-3675.
22.Male C,Chait P,Andrew M,et al.Central venous line related thrombosis in children association with central venous line location and insertion technique[J].Blood,2003;101 (11):4273-4278.
23.Bergqvist D,Agnelli G,Cohen AT,et al.Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer[J].N Engl J Med,2002,346:975-980.
24.Rasmussen MS.Preventing thromboembolic complications in cancer patients after surgery:A role for prolonged thromboprophylaxis[J].Cancer Treatment Rev,2002,28 (3):141-144.
25.Levine M,Hirsh J,Gent M,et al.Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer[J].Lancet,1994,359 (4):886-889.
26.Karen BG,Roy LS.Hypercoagulability in cancer[J].Hematol Oncol Clin North Am,1996,10 (2):499-530.
27.Levine MN.Managing thromboembolic disease in the cancer patients:efficacy and safety of antithrombotic treatment options in patients with cancer[J].Cancer Treat Rev,2002,28 (3):145-149.
28.Thodiyil P,Kakkar AK.Can low2molecular2weight heparins improve outcome in patients with cancer ?[J].Cancer Treat Rev,2002,28 (3):151-155.
29.Hutten BA,Prins MH,Gent M,et al.Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio:a retrospective analysis[J].J Clin Oncol,2000,18(17):3078-3083.
30.Buller H R,Agnelli G,Hull R,et al.Antit hrombotic t herapy forvenous thromboembolic disease:the Seventh.ACCP Conferenceon Antithrombotic and ThrombolyticTherapy[J].Chest,2004,126 (Suppl 3):401-428.
31.Deitcher S R.Cancer2related deep venous thrombosis:clinical importance,treatment challenges,and management strategies[J].Semin Throm b Hemost,2003,29 (3):247-258.
32.Decousus H,Leizorovicz A,Parent F.A clinical trial of venacaval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis[J].N Eng J Med,1998,338(7):409-415.
33.Prandoni P,Piccioli A.Venous thromboembolism and cancer:A twoway clinical association[J].Front Biosc,1997,2:el2—20.
1.Gouin-Thibault I,Samama MM.Laboratory diagnosis of the thrombophilic state in cancer patients[J].Clin Adv Hematol Oncol,2003,1(11):668-671.
2.Lip GY,Chin BS,Blann AD,et al.Cancer and the prothrombotic state[J].Lancet Oncol,2002,3(1):27-34.
3.何瑞芝.丹参的药理作用及其临床应用[J].云南医药,1986,7(4):242-243.
4.郑大为,栾杰男.碟脉灵注射液对血瘀证治疗前后血液流变学观察[J].医药世界,2006,11(2):27-28.
5.中国抗癌协会.新编常见恶性肿瘤诊治规范(第九分册)-原发性支气管肺癌[M].北京:中国协和医科大学出版社,1999.773-781.
6.孙燕,石远凯.临床肿瘤内科手册[M].人民卫生出版社,2007,399-401.
7.沈自尹,王文健.中医虚证辨证参考标准[J].中西医结合杂志,1986,6(10):598.
8.朱文锋.中医诊断学[M].上海科技出版社,2005.
9.王永炎.中医内科学.[M].1994.
10.程绍恩,夏洪生.中医证候诊断治疗学[M].北京:科学技术出版社,1993.
11.王阶,姚魁武.血瘀证诊断标准研究述要及思考[J].中国中医药信息杂志,2004,11(1):17-19.
12.国家技术监督局.中医临床诊疗术语[M].北京:中国标准出版社,1997.
13.胡小梅,张培彤,杨宗艳,等.中晚期非小细胞肺癌患者中医证型分布规律研究[J].中国肿瘤,2007,16(1):51-52.
14.候丽,姜苗,陈信义,等.晚期非小细胞肺癌中医证候特征回顾性临床研究[J].中国中医药信息杂志,14(4):19-20.
15.齐清会.腹部手术后和重症急腹症患者胃阴虚的研究[J].中西医结合杂志,1990,10(1):162.162-163.
16.胡庆福,陈泽霖,戴豪良,等.阴虚光剥舌形成机理的研究[J].中西医结合杂志,1989,9(3):153-154.
17.刘春秋.肺癌患者凝血状态变化的观察[J].河北医药,2007,29(9):929-930.
18.赵建荣,张开资.恶性肿瘤患者不同阶段凝血功能及血小板变化分析[J].华北煤炭学院学报,2006,8(1):84-85.
19.徐成伟,王芳,吴文秀等.肿瘤患者凝血及纤溶状态的改变[J].齐鲁医学检验,2003,14(3):10-11.
20.Unsal E,Atalay F,Atikcn S,Yilmaz A.Prognostic significance of hemostatic parameters in patients with lung cancer[J].Respir Med,2004,98(2):93-98.
21.Piccioli A,Prandoni P,Ewenstein BM,et al.Cancer and venous thromboembolism[J].Am Heart J,1996,132(4):850-855.
22.田斌,田忠.正常人与肿瘤患者血液流变学微循环数字成像半定量分析比较[J].中国现代普通外科进展,2006,9(6):375-376.
23.Nitori N,Ino Y,Nakanishi Y,et al.Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma[J].Clin Cancer Res,2005,11(7):2531-2539.
24.Donati MB,Lorenzet R.Coagulation factors and tumor cell biology;the role of tissue fator[J].Pathophsio haemost thromb.2003,33(supple 1):22-25.
25.Wojtukiewicz MZ,Sierko E,Zacharski LR,et al.Tissue factor-dependent coaugulation activiation and impaired fibrinolysis in gastric cancer[J].Semin Thromb Hemost,2003,29(3):291-299.
26.Monreal M,Prandoni P.Venous thromboembolism as first manifestation of cancer[J].Seminars in Thrombosis and Hemastasis,1999,25(2):131-135.
27.薛松,朱成全,肖烈钢.加味四君固本汤对恶性肿瘤患者血液流变性和甲襞微循环的影响[J].安徽中医学院学报,2006,25(5):9-10.
28.顾小侠,刘书林,陶玉华.参麦合葛根注射液改善恶性肿瘤高凝状态45例观察[J].浙江中医杂志,2005,40(9):413.
29.罗长义.益气养阴抗肿瘤的动物实验研究[J].甘肃中医,1999,12(4):51-54.3
0.孙慧莉,施志明,赵丽红,等.益气养阴方对中晚期原发性非小细胞肺癌患者免疫功能的影响[J].中医药临床杂志,2005,17(5):474-475.
31.刘鲁明,吴良村,林胜友,等.参麦注射液对非小细胞肺癌化疗减毒作用[J].浙江中西医结合杂志,2000,10(6):322-323.
32.丁罡,宋明志,于尔辛,等1丹参、赤芍对大鼠walker256癌肝转移影响机制的研究[J].中国癌症杂志,2001,11(4):364-366.
33.徐德成,张培宇.活血化瘀强度与气血双亏型胃癌转移率相关性机理探讨[J].中医杂志,1998,39(3):156-157.
34.李道睿,张培彤,胡晓梅,等.300例中晚期原发性支气管肺癌血瘀证分布规律的调查研究[J].中国中医药信息杂志,2007,14(3):19-21.
35.陈泽民,李泽浩,江建平,等.肝癌病人舌质与微循环的关系-附100例临床分析(J].中西医结合肝病杂志,1999,9(3):44-45.
36.Milanini Mongiat J,Pouyssegur J,Pages G.Identification of two Spl phosphorylation sites for p42 /p44 mitogen-activated protein kinases:their implication in vascular endothelial growth factor gene transcription[J].J Biol Chem,2002,277(3):20631-20639.
37.Berra E,Milanini J,Richard DE,et al.Signaling angiogenesis via p42 /p44 MaP kinase and hypoxia[J].Biochem Pharmacol,2000,60(8):1171-1178.
38.Bogatcheva NV,Garcia JG,Verin AD.Molecular mechanisms of thrombin induced endothelial cell permeability[J].Biochemistry(Mosc),2002,67(1):75-84.
39.Karpatkin S.Does hypercoagulability awaken dormant tumor cells in the host? J Thromb Haemost[J],2004,2(12):2103-2106.
40.Yin YJ,Salah Z,Grisaru-Granovsky S,Cohen I,Cohen Even-Ram S,Maoz M,Uziely B,Bar-Shavit R.Human protease-activated receptor 1 expression in malignant epithelia:a role in invasiveness[J].Arterioscler Thromb Vasc Biol,2003,23(6):940-944.
41.Tsopanoglou NE,MaragoudakisME.Role of thrombin in angiogenesis and tumor progression[J].Semin Thromb Hemost,2004,30(1):63-69.
42.Rickles FR,Patierno S,Fernandez PM.Tissue factor,thrombin,and cancer[J].Chest,2003,124(Supp-13):58S-68s.
43.Ruf W,Dorfleutner A,Riewald M.Specificity of coagulation factor signaling.J Thromb Haemost[J],2003,1(7):1495-1503.
44.汤坚强,万远廉,刘玉村,等.组织因子促进人类大肠癌细胞的侵袭及与基质金属蛋白酶的相关性研究[J].北京大学学报,2005,37(3):265-268.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |